The medicinal use of water in renal disease

Kidney International

Volumn 84, Issue 1, 2013, Pages 45-53

  Wang, Connie J ^a   Grantham, Jared J ^a   Wetmore, James B ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VASOPRESSIN RECEPTOR; WATER;

ADULT; AGED; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIURESIS; FAMILY HISTORY; FLUID INTAKE; FLUID THERAPY; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY CYST; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY POLYCYSTIC DISEASE; MAJOR CLINICAL STUDY; NEPHROLITHIASIS; PATIENT COMPLIANCE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SECONDARY PREVENTION; SOLUTE; URINE OSMOLALITY; URINE VOLUME;

EID: 84879689628     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.23     Document Type: Review

References (71)

1. Jones PA, Ross RK. Prevention of bladder cancer. N Engl J Med 1999; 340: 1424-1426.
2. Lubin F, Rozen P, Arieli B et al. Nutritional and lifestyle habits and waterfiber interaction in colorectal adenoma etiology. Cancer Epidemiol Biomarkers Prev 1997; 6: 79-85.
3. Chan J, Knutsen SF, Blix GG et al. Water, other fluids, and fatal coronary heart disease: the Adventist Health Study. Am J Epidemiol 2002; 155: 827-833.
4. Clark WF, Sontrop JM, Macnab JJ et al. Urine volume and change in estimated GFR in a community-based cohort study. Clin J Am Soc Nephrol 2011; 6: 2634-2641.
5. Strippoli GF, Craig JC, Rochtchina E et al. Fluid and nutrient intake and risk of chronic kidney disease. Nephrology (Carlton) 2011; 16: 326-334.
6. Higashihara E, Torres VE, Chapman AB et al. Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience. Clin J Am Soc Nephrol 2011; 6: 2499-2507.
7. Nagao S, Nishii K, Katsuyama M et al. Increased water intake decreases progression of polycystic kidney disease in the PCK rat. J Am Soc Nephrol 2006; 17: 2220-2227.
8. Curhan GC, Willett WC, Speizer FE et al. Comparison of dietary calcium with supplemental calcium and other nutrients as factors affecting the risk for kidney stones in women. Ann Intern Med 1997; 126: 497-504.
9. Taylor EN, Stampfer MJ, Curhan GC. Dietary factors and the risk of incident kidney stones in men: new insights after 14 years of follow-up. J Am Soc Nephrol 2004; 15: 3225-3232.
10. Curhan GC, Willett WC, Knight EL et al. Dietary factors and the risk of incident kidney stones in younger women: Nurses' Health Study II. Arch Int Med 2004; 164: 885-891.
11. Curhan GC, Willett WC, Rimm EB et al. Family history and risk of kidney stones. J Am Soc Nephrol 1997; 8: 1568-1573.
12. Kavanagh JP. Calcium oxalate crystallization in vitro. In: Khan SR (ed). Calcium Oxalate in Biological Systems. CRC Press: Boca Raton, FL, USA, 1995.
13. Blacklock NJ. The pattern of urolithiasis in the Royal Navy. In: Nordin BEC, Hodgkinson A (eds). Proceedings of the Renal Stone Research Symposium. Churchil: London, UK, 1969 p 235.
14. Frank M, De Vries A, Atsmon A et al. Epidemiological investigation of urolithiasis in Israel. J Urol 1959; 81: 497-505.
15. Strauss AL, Coe FL, Deutsch L et al. Factors that predict relapse of calcium nephrolithiasis during treatment: a prospective study. Am J Med 1982; 72: 17-24.
16. Hosking DH, Erickson SB, Van den Berg CJ et al. The stone clinic effect in patients with idiopathic calcium urolithiasis. J Urol 1983; 130: 1115-1118.
17. Embon OM, Rose GA, Rosenbaum T. Chronic dehydration stone disease. Br J Urol 1990; 66: 357-362.
18. Daudon M, Hennequin C, Boujelben G et al. Serial crystalluria determination and the risk of recurrence in calcium stone formers. Kidney Int 2005; 67: 1934-1943.
19. Borghi L, Meschi T, Amato F et al. Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5-year randomized prospective study. J Urol 1996; 155: 839-843.
20. Sarica K, Inal Y, Erturhan S et al. The effect of calcium channel blockers on stone regrowth and recurrence after shock wave lithotripsy. Urol Res 2006; 34: 184-189.
21. Fuss M, Simon J, Fontinoy N et al. High fluid-low calcium intake: not all renal stone formers adhere to this simple treatment. Eur Urol 1979; 5: 97-99.
22. Kunau RT. Nephrology and Hypertension. Medical Knowledge Self- Assessment Program, 2nd edn. American College of Physicians: Philadelphia, PA, USA, 1998.
23. Stefanski A, Ritz E, Amann K. Factors affecting progression of renal failure-experimental data. In: Kopple JD, Massry SG (eds). Nutritional Management of Renal Disease. Williams & Wilkins: Baltimore, MD, USA, 1997 pp 277-316.
24. Pitts RE. Physiology of the Kidney and Body Fluids, 3rd edn. Yearbook Medical Publisher 1974.
25. Anastasio P, Cirillo M, Spitali L et al. Level of hydration and renal function in healthy humans. Kidney Int 2001; 60: 748-756.
26. McCance RA, Young WF, Black DA. The secretion of urine during dehydration and rehydration. J Physiol 1944; 102: 415-428.
27. Bouby N, Bachmann S, Bichet D et al. Effect of water intake on the progression of chronic renal failure in the 5/6 nephrectomized rat. Am J Physiol 1990; 258: F973-F979.
28. Sugiura T, Yamauchi A, Kitamura H et al. High water intake ameliorates tubulointerstitial injury in rats with subtotal nephrectomy: possible role of TGF-beta. Kidney Int 1999; 55: 1800-1810.
29. Bardoux P, Bichet DG, Martin H et al. Vasopressin increases urinary albumin excretion in rats and humans: involvement of V2 receptors and the renin-angiotensin system. Nephrol Dial Transplant 2003; 18: 497-506.
30. Bouby N, Ahloulay M, Nsegbe E et al. Vasopressin increases glomerular filtration rate in conscious rats through its antidiuretic action. J Am Soc Nephrol 1996; 7: 842-851.
31. Bardoux P, Martin H, Ahloulay M et al. Vasopressin contributes to hyperfiltration, albuminuria, and renal hypertrophy in diabetes mellitus: study in vasopressin-deficient Brattleboro rats. Proc Natl Acad Sci USA 1999; 96: 10397-10402.
32. Zong HY, Wang KR, Xie XL. Effects of long-term fertilization on soil organic nitrogen components in paddy soil derived from red earth. [Ying yong sheng tai xue bao=The journal of applied ecology/Zhongguo sheng tai xue xue hui, Zhongguo ke xue yuan Shenyang ying yong sheng tai yan jiu suo zhu ban] 2008; 19: 1721-1726.
33. Perucca J, Bichet DG, Bardoux P et al. Sodium excretion in response to vasopressin and selective vasopressin receptor antagonists. J Am Soc Nephrol 2008; 19: 1721-1731.
34. Bankir L, Bichet DG, Bouby N. Vasopressin V2 receptors, ENaC, and sodium reabsorption: a risk factor for hypertension? Am J Physiol Renal Physiol 2010; 299: F917-F928.
35. Schweda F, Klar J, Narumiya S et al. Stimulation of renin release by prostaglandin E2 is mediated by EP2 and EP4 receptors in mouse kidneys. Am J Physiol Renal Physiol 2004; 287: F427-F433.
36. Ruster C, Wolf G. Renin-angiotensin-aldosterone system and progression of renal disease. J Am Soc Nephrol 2006; 17: 2985-2991.
37. Ganz MB, Pekar SK, Perfetto MC et al. Arginine vasopressin promotes growth of rat glomerular mesangial cells in culture. Am J Physiol 1988; 255: F898-F906.
38. Higashiyama M, Ishikawa S, Saito T et al. Arginine vasopressin inhibits apoptosis of rat glomerular mesangial cells via V1a receptors. Life Sci 2001; 68: 1485-1493.
39. Torres VE. Vasopressin in chronic kidney disease: an elephant in the room? Kidney Int 2009; 76: 925-928.
40. Brooks DR, Ramirez-Rubio O, Amador JJ. CKD in Central America: a hot issue. Am J Kidney Dis 2012; 59: 481-484.
41. Peraza S, Wesseling C, Aragon A et al. Decreased kidney function among agricultural workers in El Salvador. Am J Kidney Dis 2012; 59: 531-540.
42. Hebert LA, Greene T, Levey A et al. High urine volume and low urine osmolality are risk factors for faster progression of renal disease. Am J Kidney Dis 2003; 41: 962-971.
43. Wang X, Lewis J, Appel L et al. Validation of creatinine-based estimates of GFR when evaluating risk factors in longitudinal studies of kidney disease. J Am Soc Nephrol 2006; 17: 2900-2909.
44. Windt WA, Tahara A, Kluppel AC et al. Early, but not late therapy with a vasopressin V1a-antagonist ameliorates the development of renal damage after 5/6 nephrectomy. J Renin Angiotensin Aldosterone Syst 2006; 7: 217-224.
45. Magpantay L, Ziai F, Oberbauer R et al. The effect of fluid intake on chronic kidney transplant failure: a pilot study. J Renal Nutr 2011; 21: 499-505.
46. Vaamonde CA, Presser JI, Clapp W. Effect of high fluid intake on the renal concentrating mechanism of normal man. J Appl Physiol 1974; 36: 434-439.
47. Spigt MG, Knottnerus JA, Westerterp KR et al. The effects of 6 months of increased water intake on blood sodium, glomerular filtration rate, blood pressure, and quality of life in elderly (aged 55-75) men. J Am Geriatr Soc 2006; 54: 438-443.
48. Passfall J, Pai J, Spies KP et al. Effect of water and bicarbonate loading in patients with chronic renal failure. Clin Nephrol 1997; 47: 92-98.
49. U.S. Renal Data System. Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD, USA, 2011.
50. Torres VE, Bankir L, Grantham JJ. A case for water in the treatment of polycystic kidney disease. Clin J Am Soc Nephrol 2009; 4: 1140-1150.
51. Torres VE. Water for ADPKD? Probably, yes. J Am Soc Nephrol 2006; 17: 2089-2091.
52. Grantham JJ. Therapy for polycystic kidney disease? It's water, stupid! J Am Soc Nephrol 2008; 19: 1-7.
53. Grantham JJ. Clinical practice. Autosomal dominant polycystic kidney disease. N Engl J Med 2008; 359: 1477-1485.
54. Torres VE, Grantham JJ. Cystic diseases of the kidney. In: Brenner BM (ed). Brenner & Rector's the Kidney, 9th edn. Elsevier: Philadelphia, PA, USA, 2012 p 1626.
55. Mangoo-Karim R, Uchic M, Lechene C et al. Renal epithelial cyst formation and enlargement in vitro: dependence on cAMP. Proc Natl Acad Sci USA 1989; 86: 6007-6011.
56. Hanaoka K, Guggino WB. cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells. J Am Soc Nephrol 2000; 11: 1179-1187.
57. Yamaguchi T, Pelling JC, Ramaswamy NT et al. cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway. Kidney Int 2000; 57: 1460-1471.
58. Belibi FA, Reif G, Wallace DP et al. Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells. Kidney Int 2004; 66: 964-973.
59. Gattone VH 2nd, Maser RL, Tian C et al. Developmental expression of urine concentration-associated genes and their altered expression in murine infantile-type polycystic kidney disease. Dev Genet 1999; 24: 309-318.
60. Gattone VH 2nd, Wang X, Harris PC et al. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 2003; 9: 1323-1326.
61. Torres VE, Wang X, Qian Q et al. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med 2004; 10: 363-364.
62. Wang X, Gattone V 2nd, Harris PC et al. Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol 2005; 16: 846-851.
63. Reif GA, Yamaguchi T, Nivens E et al. Tolvaptan inhibits ERK-dependent cell proliferation, Cl secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin. Am J Physiol Renal Physiol 2011; 301: F1005-F1013.
64. Torres VE, Chapman AB, Devuyst O et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012; 367: 2407-2418.
65. Wang CJ, Creed C, Winklhofer FT et al. Water prescription in autosomal dominant polycystic kidney disease: a pilot study. Clin J Am Soc Nephrol 2011; 6: 192-197.
66. Barash I, Ponda MP, Goldfarb DS et al. A pilot clinical study to evaluate changes in urine osmolality and urine cAMP in response to acute and chronic water loading in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2010; 5: 693-697.
67. Veelken R, Danckwart L, Rohmeiss P et al. Effects of intravenous AVP on cardiac output, mesenteric hemodynamics, and splanchnic nerve activity. Am J Physiol 1989; 257: H658-H664.
68. Izzo JL, Sica DA, Black HR. (eds).Chapter A22: Vasopressin and neuropeptide Y. Hypertension Primer: the Essentials of High Blood Pressure: Basic Science, Population Science, and Clinical Management, 4th edn. Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2008, p 71.
69. Schrier RW, Gross P, Gheorghiade M et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006; 355: 2099-2112.
70. Robinson AG. Disorders of antidiuretic hormone secretion. Clin Endocrinol Metab 1985; 14: 55-88.
71. Perucca J, Bouby N, Valeix P et al. Sex difference in urine concentration across differing ages, sodium intake, and level of kidney disease. Am J Physiol Regul Integr Comp Physiol 2007; 292: R700-R705.